Future DES Purchasing Strategy: A “Price Is Right” Approach?
This article was originally published in The Gray Sheet
Executive Summary
Pricing strategies and ease of use factors likely will overshadow clinical efficacy as Boston Scientific and Johnson & Johnson joust for dominance in the U.S. drug-eluting stent market